37 completed, 8 recruiting, 3 unknown, 3 withdrawn. 55 Phase 2, 9 Phase 1, 5 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 55 | Completed 37, Recruiting 8, Unknown 3, Withdrawn 3, Terminated 2, Not yet recruiting 1, Suspended 1 |
| Phase 1 | 9 | Completed 4, Recruiting 4, Unknown 1 |
| Phase 3 | 5 | Completed 3, Unknown 2 |
Follow Fluoxetine: new trials by email Literature Review of Fluoxetine trials Research Report on Fluoxetine
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Evaluation of Fluoxetine for Refractory Constipation With Somatic Symptom Disorder Features Fluoxetine, Placebo - Refractory Constipation, Somatic Symptom Disorder (DSM-5) | Phase 2 | Not yet recruiting | Zhifeng Zhao, PhD | 194 | 2026-09-01 | 2026-09-02 |
| Clinical Trials to Evaluate Metformin to Treat Depression in People Living With HIV Metformin, Placebo, Fluoxetine - Depression, Hiv | Phase 2 | Withdrawn | University of Minnesota | 2026-07-01 | 2026-07-10 | |
| Dapagliflozin in Depression Fluoxetine, Dapagliflozin - Depression | Phase 1 / Phase 2 | Recruiting | Tanta University | 60 | 2025-11-01 | 2025-11-25 |
| SSRI Antidepressant Fluoxetine Improving Immunotherapy Efficacy in Advanced Hepatobiliary Malignancy Patients With Depression and Anxiety Fluoxetine (drug), Placebo - Hepatobiliary Malignancy, Fluoxetine | Phase 2 | Recruiting | First Affiliated Hospital of Wenzhou Medical University | 240 | 2025-10-01 | 2026-03-24 |
| Psilocybe Cubensis Mushrooms With or Without Fluoxetine for Refractory Depression Psilocybin and Psilocyn, Placebo, Psychotherapy-assisted session - Depressive Disorder | Phase 1 / Phase 2 | Recruiting | Federal University of Latin American Integration | 24 | 2024-09-05 | 2026-03-27 |
| Clinical Study to Evaluate the Possible Efficacy of Dapagliflozin and Atorvastatin in Patients With Major Depressive Disorders Fluoxetine 20 mg, Dapagliflozin 10mg Tab, Atorvastatin 80mg - Depressive Disorder | Phase 2 | Completed | Tanta University | 75 | 2023-06-06 | 2026-10-30 |
| Sequenced Treatment Alternatives to Relieve Adolescent Depression (STAR-AD) Fluoxetine, Sertraline, Vortioxetine - Depression, Sequestra | Phase 1 / Phase 2 | Recruiting | First Affiliated Hospital of Chongqing Medical University | 520 | 2023-02-20 | 2026-01-27 |
| Study of Dextromethorphan in OCD and Related Disorders Fluoxetine, Dextromethorphan - Obsessive-Compulsive Disorder, Illness Anxiety Disorder | Phase 2 | Recruiting | Stanford University | 60 | 2022-01-20 | 2026-05-20 |
| TDCS in Pediatric and Teenage Patients With Major Depressive Disorder During COVID-19 Pandemic Transcranial Direct Current Stimulation, Placebo-simulation of transcranial direct current stimulation, Fluoxetine Tablets - Major Depressive Disorder | Phase 2 / Phase 3 | Unknown | El Instituto Nacional de Neurologia y Neurocirugia Manuel Velasco Suarez | 172 | 2021-10-01 | 2021-06-04 |
| Finding Treatments for COVID-19: A Trial of Antiviral Pharmacodynamics in Early Symptomatic COVID-19 (PLATCOV) Nirmatrelvir/ritonavir (e.g. PAXLOVID™), Nitazoxanide, Molnupiravir and nirmatrelvir/ritonavir (e.g. PAXLOVID™) - COVID-19 | Phase 2 | Recruiting | University of Oxford | 3800 | 2021-09-30 | 2026-02-19 |
| Fluoxetine Mitigation Mental Health Study for Patients With Musculoskeletal Trauma Fluoxetine, Calcium - Musculoskeletal Injury | Phase 2 | Completed | University of Florida | 55 | 2021-09-01 | 2026-05-14 |
| Early Treatment of Vulnerable Individuals With Non-Severe SARS-CoV-2 Infection Nitazoxanide and Ciclésonide, Telmisartan 20Mg Oral Tablet, Paracetamol - Covid19, Covid19 Drug Treatment | Phase 2 / Phase 3 | Unknown | ANRS, Emerging Infectious Diseases | 600 | 2021-04-12 | 2023-01-31 |
| Measuring Ambulation, Motor, and Behavioral Outcomes With Post-Stroke Fluoxetine in Tanzania Fluoxetine 20 MG Oral Tablet - Acute Stroke, Stroke, Ischemic | Phase 2 | Completed | Massachusetts General Hospital | 34 | 2019-11-26 | 2022-05-25 |
| Brain Network Changes Accompanying and Predicting Responses to Pharmacotherapy in OCD Fluoxetine - immediate treatment, Fluoxetine - delayed treatment - Obsessive-Compulsive Disorder | Phase 1 / Phase 2 | Recruiting | Yale University | 100 | 2019-10-14 | 2026-09-22 |
| Poststroke Depression in Hemorrhagic Stroke Fluoxetine, Placebo - Stroke Hemorrhagic, Depression | Phase 2 | Completed | University of Washington | 8 | 2019-03-01 | 2025-08-06 |
| Fluoxetine Opens Window to Improve Motor Recovery After Stroke Fluoxetine Hydrochloride, Placebo, Exercise Program - Stroke, Cerebrovascular Accident | Phase 2 | Completed | University Health Network, Toronto | 52 | 2019-01-01 | 2022-11-04 |
| Abnormal Ventilatory Response to Carbon Dioxide: a Potential Biomarker for Seizure Induced Respiratory Depression & Modification by SSRI Fluoxetine, Placebo - Epilepsy, SUDEP | Phase 2 | Completed | Rup Kamal Sainju | 30 | 2017-02-16 | 2020-05-04 |
| RCT of a Neuroplasticity Agent and CI Therapy for Severe Arm Paresis After Stroke Fluoxetine, Placebo, eCMIT - Severe Stroke With Affected Arm Motor Function | Phase 2 | Withdrawn | University of Alabama at Birmingham | 2016-11-01 | 2015-01-12 | |
| Fluoxetine for Visual Recovery After Ischemic Stroke Fluoxetine, Placebo - Acute Stroke, Visual Field Loss | Phase 2 | Terminated | Bogachan Sahin | 17 | 2016-05-01 | 2021-10-13 |
| Hierarchical Treatment Based on Somatization Symptom Checklist Deanxit, Prozac, coronary artery disease treatment - Syndrome X | Phase 1 / Phase 2 | Unknown | RenJi Hospital | 200 | 2015-12-01 | 2020-03-04 |
Showing 20 of 55. Sign in to see all of them.
Depression (14) · Depressive Disorder, Major (9) · Stroke (6) · Depressive Disorder (4) · Anxiety Disorders (3) · COVID-19 (3) · Ischemic Stroke (3) · Obsessive-Compulsive Disorder (3) · Acquired Immunodeficiency Syndrome (2) · Autistic Disorder (2) · Dysthymic Disorder (2) · Fatigue (2) · Pulmonary Arterial Hypertension (2) · Adenocarcinoma of Lung (1) · Aggression (1)
New York State Psychiatric Institute (3) · University of Minnesota (3) · University of Pittsburgh (3) · Massachusetts General Hospital (2) · Tanta University (2) · University Hospital, Toulouse (2) · University of Texas Southwestern Medical Center (2) · ANRS, Emerging Infectious Diseases (1) · Alliance for Clinical Trials in Oncology (1) · Assistance Publique - Hôpitaux de Paris (1) · Bogachan Sahin (1) · Brigham and Women's Hospital (1) · Centro Medico Teknon (1) · Chengdu University of Traditional Chinese Medicine (1) · El Instituto Nacional de Neurologia y Neurocirugia Manuel Velasco Suarez (1)
United States (33) · China (4) · Mexico (3) · Brazil (2) · Egypt (2) · France (2) · Burkina Faso (1) · Canada (1) · Guinea (1) · Iran (1) · Laos (1) · Nepal (1) · Pakistan (1) · Puerto Rico (1) · Spain (1)
Meredith Gunlicks-Stoessel, PhD (2) · Akbar Fotouhi, MD, PhD (1) · Al Rivera, MD (1) · Albert Nadal, MD (1) · Andrew W Goddard, MD (1) · Arash Etemadi, MD, PhD (1) · Arthur J. Barsky, MD (1) · Behtash Saeidi, MD (1) · Bradley MacIntosh, PhD (1) · Brian Fallon, MD (1) · Carl Gommoll, MS (1) · Christopher Pittenger, MD, PhD (1) · Courtney Pollock, PhD (1) · Daniel S Pine, M.D. (1)
PMID 10990547, PMID 11063978, PMID 11723286, PMID 12244081, PMID 12949224, PMID 14677403, PMID 15147306, PMID 15351385, PMID 15365580, PMID 15987799, PMID 16002441, PMID 16794566, PMID 17414235, PMID 17591596, PMID 18053120, PMID 18061147, PMID 18314433, PMID 19182688, PMID 19223438, PMID 19321268, PMID 19332318, PMID 19403329, PMID 19414708, PMID 19485586, PMID 19671217, PMID 19730273, PMID 19730274, PMID 19853048, PMID 19858762, PMID 19968380, PMID 20008943, PMID 20478877, PMID 20576364, PMID 20633386, PMID 20673556, PMID 21068312, PMID 21167786, PMID 21192150, PMID 21208583, PMID 21216670, PMID 21334569, PMID 21383263, PMID 21515198, PMID 21631313, PMID 21784297, PMID 21890211, PMID 22024002, PMID 22032743, PMID 22189047, PMID 22193671
K24MH121571 (1), R01AA013370 (1), R01AA015173 (1), R01DA006234 (1), R01DA019142 (1), R01MH063011 (1), R01MH066984 (1), R01MH071688 (1), R01MH116038 (1), U01MH061835 (1), U01MH093582 (1), U10CA031946 (1), U10MH066750 (1), U10MH066762 (1), U10MH066769 (1)